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Despite size and relevance of non-adherence to health treatments, robust evidence on its effects on 
health care utilisation is very limited. We focus on non-adherence to diabetes treatments, a 
widespread problem, and employ longitudinal administrative data from Spain (2004-2010) to identify 
and quantify the effects of uncontrolled type 2 diabetes on health care utilisation. We use a biomarker 
(glycated haemoglobin, HbA1c) to detect the presence of uncontrolled diabetes and explore its effects 
on both primary and secondary health care. We estimate a range of panel count data models, including 
negative binomials with random effects, dynamic and hurdle specifications to account for unobserved 
heterogeneity, previous utilisation and selection. We find uncontrolled diabetes in around 30% of 
patients of both genders. Although women appear to systematically consume more health care 
compared to men, their consumption levels do not appear to be influenced by uncontrolled diabetes. 
Conversely, among men uncontrolled diabetes increases the average number of GP visits per year by 
around 4%, specialist visits by 4.4% and greatly extends hospital length of stay.  
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The medical literature consistently finds that around 20 to 50% of patients worldwide do not 
adhere to medical treatments.  This has potential serious consequences for their health and in 
terms of increasing costs for the health care system (e.g. Haynes et al., 2002; DiMatteo, 2004; 
Sokol et al., 2005; Kripalani et al., 2007). Non-adherence concerns about 50% of individuals 
suffering from chronic health conditions (see e.g. Jackevicius et al., 2002, and Osterberg and 
Blaschke, 2005) and has been defined by the WHO (2003) as a worldwide problem of 
substantial importance.  Furthermore, low or non-adherence may reduce benefits of health 
treatments and distort the assessment of their effectiveness (e.g. Vander Stichele, 1991). 
Among individuals with diabetes mellitus (DM), the most prevalent chronic disease in nearly 
all countries (International Diabetes Federation (IDF) Diabetes Altas, 2014), adherence to 
treatment is defined as the extent to which patients comply with the agreed recommendations 
on lifestyles and medications from the health care provider (WHO, 2003; Garcia-Perez et al., 
2013).4 Among patients with DM non-adherence is especially common, leading to 
uncontrolled diabetes (i.e. poor glycaemic control resulting in higher levels of blood sugar or 
hyperglycemia) and potentially exposing individuals to higher risks of life-threatening 
comorbidities such as heart disease and stroke as well as vision problems and blindness (Ho 
et al., 2006; Mayo Clinic, 2014).  
The detrimental effects of non-adherence to diabetes treatments and the resulting condition of 
uncontrolled diabetes are likely to be exacerbated by the increasing prevalence of DM. 
According to the WHO (2016), we are currently experiencing a global diabetes epidemic with 
DM affecting 422 million adult individuals worldwide in 2014, compared to 108 million in 
1980 and projected to be 7th leading cause of death by 2030. In the U.S. alone, the estimated 
total costs of diagnosed diabetes increased by 41% in a five year period, from $174 billion in 
2007 to an estimated $245 billion in 2012 (American Diabetes Association, 2013). In the UK 
the cost of diabetes to the NHS is over £1.5m an hour or 10% of the NHS budget for England 
and Wales (UK Diabetes Global Health Community, 2014).  
A related problem may be caused by the additional health care utilisation and in turn the extra 
costs caused by uncontrolled diabetes. Individuals with uncontrolled diabetes may potentially 
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 Recommendations on lifestyles often include an exercise regimen as well as a low-carbohydrate and low-fat 
diet. In early stages of DM, these might be followed by medications such as oral hypoglycaemic agents and later 
on by injectable treatments. For further information, see recommendations from the International Diabetes 
Federation (IDF), the umbrella organisation of 230 national diabetes associations from 170 countries, 
http://www.idf.org/.           
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use more health care resources resulting in extra utilisation and extra costs for the health 
system as well as further loss in productivity due to work absence, work limitations, lower 
earnings and early mortality (e.g. Ng et al., 2001; Bastida and Pagan, 2002; Tunceli et al., 
2005).  
Whereas non-adherence and uncontrolled diabetes are widespread phenomena, robust 
evidence on their effects on health care utilisation is very limited. Furthermore, the previous 
medical evidence is often based on selected samples, mostly from U.S. health insurance 
claims, and standard methods such as linear regression models. Selected samples would limit 
the generalisability of the results while standard linear models would not account for 
potentially relevant issues such as unobserved heterogeneity and selection which may affect 
the estimates of the effects of non-adherence. A more accurate assessment of the health care 
consequences of uncontrolled diabetes would help enhancing the evidence based for 
physicians to better plan treatments and for policy-makers to develop cost-effective 
interventions to increase adherence rates and reduce excess utilisation leading to resource 
inefficiencies. 
The main objective of this paper is to identify and quantify changes in healthcare utilisation 
driven by uncontrolled diabetes. We employ seven waves (2004-2010) of a longitudinal and 
large administrative dataset of detailed medical records of adult diabetic patients from the 
province of Barcelona, Spain. Our data covers a wide range of individual-level clinically 
assessed biomarkers and health variables. We measure uncontrolled diabetes using glycated 
haemoglobin (HbA1c) levels. HbA1c is a biomarker providing an accurate average 
measurement of glucose (sugar) concentration and is commonly used by physicians to 
diagnose and monitor diabetes as well as its level of severity (e.g. International Expert 
Committee, 2009; Lyons and Basu, 2012). We focus on the effects of uncontrolled diabetes 
on both primary care and secondary care (number of visits to general practitioners, GP, and 
specialists) as well as hospital length of stay (i.e. number of days in hospital).       
We exploit the longitudinal nature of the data and estimate a succession of panel count data 
models, including random effects negative binomials as well as dynamic and hurdle 
specifications to account for unobserved heterogeneity, previous utilisation and potential 
selection issues. We find that patients with uncontrolled diabetes appear to increase their 
annual use of primary health care by around 4% and the one of specialist visits by around 
4.4%. Uncontrolled diabetes appears to greatly extend length of stay (17.4%), conditional on 
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positive stays. However, these effects appear to be mainly concentrated among men and 
differ according to the level of uncontrolled diabetes. A series of robustness checks validate 
our main findings.   
This paper offer several contributions to the literature. First, to the best of our knowledge, this 
is one of the first papers focusing on the effects of non-adherence on health care utilisation 
within the health economics literature. Secondly, we combine the use of longitudinal data 
with biomarkers from a large set of adult diabetic patients to quantify the effects of 
uncontrolled diabetes, a prevalent condition, on health care utilisation by employing robust 
panel data econometric methods. Finally, we go beyond studies based on US health insurance 
enrolees and present evidence based on rich administrative data from a European country. 
More broadly, we advance the literature by merging the medical literature on non-adherence 
and diabetes care with the economics literature on health care utilisation to produce a new 
evidence base for better informed interventions.  
The paper proceeds as follows. Section 2 provides an overview of the previous literature 
while sections 3 and 4 describe the data and outlines our empirical approach, respectively. 
Section 5 presents our main results and section 6 concludes and discusses our findings. 
2. Background 
Wagner et al. (2001) employ US insurance claims data of adult diabetics from a large Health 
Maintenance Organization (HMO) in Seattle (state of Washington) between 1992-1997 to 
analyse the association between improved glycaemic control and health care utilisation and 
costs. They employ standard linear and log-linear regression models and find that sustained 
reduction of HbA1c levels is correlated with lower utilisation (measured by hospitalisation 
rates as well as primary and specialty care visits) and cost savings, although cost reductions 
are significant only among patients with the highest baseline HbA1c levels (over 10%) and 
do not appear to be affected by further baseline health care conditions. Gilmer et al. (2005) 
combine both claims and survey data of diabetic adults in Minnesota with generalised linear 
models (GLM) and find that coronary heart disease (CHD), hypertension and depression are 
stronger predictors of health care costs than high baseline HbA1c levels. Interestingly, 
HbA1c levels below 7.5% were not associated with increased costs. Oglesby et al. (2006) use 
similar methods and data from the U.S. Health Core Managed Care Database between 1998-
2003 and observe that direct medical costs driven by type 2 diabetes were between 16% to 
20% lower for individuals with good glycaemic control (HbA1c ≤ 7%) Similarly, Menzin et 
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al. (2010) focus on a subsample of managed-care diabetic patients from Massachusetts 
covering a 5-year period (2002-2006) and employ logit and GLM models. They notice that 
diabetes-related hospitalisations were significantly higher among patients with highly 
uncontrolled diabetes. Based on two-part models, hospital costs per patient were also higher 
with increasing uncontrolled diabetes. 
Other studies within the economic literature have examined the economic consequences of 
diabetes by focusing mainly on its effects on the labour market. Rizzo et al. (1996) 
investigate the labour productivity of a series of chronic conditions as well as their prescribed 
medications. They employ U.S. data from the National Medical Expenditure Survey (NMES) 
and find that untreated diabetes is associated with an average of 25 days lost but that diabetes 
medications could save an average 16 days of work. Kahn (1998) investigates trends in 
diabetic employment in the U.S. by employing three different sources of data and shows that 
diabetic men appear to have decreased (although slightly) their participation between 1976-
1992. These results are extended by Latif (2009) using data from the Canadian National 
Population Health Survey and Zhang et al. (2009) on data drawn from the Australian 
National Health Survey. They find that diabetes appears to have a significant negative impact 
on female employment and that diabetes reduces labour force participation especially among 
older male individuals, respectively. Findings from Minor (2010) also indicate that diabetes 
appears to be detrimental to a number of labour market outcomes (e.g. participation, hours of 
work, out-of-work-days and earnings). More recently, Alva et al. (2014) estimate the effects 
of diabetes related complications on quality of life using UK longitudinal data from the 
Prospective Diabetes Study. Their results highlight the importance of studying changes in 
quality of life over time.  
Our paper builds on the previous medical evidence and exploits rich longitudinal 
administrative data and biomarkers combined with panel count data models to provide new 
evidence on the effects of a widespread condition, uncontrolled diabetes, on health care 
utilisation.    
3. Data 
We employ individual-level longitudinal data drawn from administrative records of patients 
followed over seven consecutive years (2004-2010) in 6 primary care centres and 2 hospitals 
in the north-east of Barcelona, in Spain serving more than 104,000 inhabitants. This sample 
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of users is mostly urban, of lower-middle socioeconomic status from a predominantly 
industrial area. 
This dataset includes a rich set of information about patients’ use of healthcare resources, 
including our three main outcomes of interest i.e., number of GP visits; specialist care and 
hospital length of stay. Analysing utilisation and its determinants is important, especially 
when hospitalisation costs are widely reported as the largest component of diabetes medical 
costs and the number of hospitalizations, re-admissions and hospital length of stay tend to 
increase with this condition.5 Our data also encompasses information on clinical 
measurements of height and weight (used to build an individual’s body mass index, BMI); 
patient’s chronic and diagnosed health conditions (classified according to the ICPC-2); dates 
of hospital admission and discharge; type of healthcare professional(s) contacted; and the 
main reason for their visit. Moreover, the dataset includes individual level socio-demographic 
characteristics such as age, gender, marital status, immigration (Spanish or EU national 
versus non-EU national) and employment status (active vs retired), place of birth and 
residence and health-behaviours (tobacco and alcohol use).6 
Given the purpose of this study we focus on a sub-sample of individuals with diagnosed type 
2 diabetes mellitus (DM), aged 16+ who had at least one contact with the aforementioned 
hospitals and primary health care centres between 1 January 2004 and 31 December 2010.7 
Individuals transferred or moved to other health centres and patients from other areas were 
excluded from our analysis. Diabetic patients were mainly identified through the International 
Classification of Primary Care codes (second edition, ICPC-2) reported by physicians 
combined with the information provided by the glycated haemoglobin test (HbA1c).8 This 
test is routinely used by physicians and provides a very accurate measure of glucose 
concentration up until the previous 8 weeks. Information from HbA1c levels, allowed the 
inclusion among our population of diabetics of those patients who might not have been 
reported as diabetics through the ICPC-2 codes but had a mean HbA1c level ≥ 6.5% (≥ 48 
mmol/mol). Following this criteria, we obtained a sample of 53,963 patients with type 2 DM.  
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 Mata-Cases et al. (2015) using data from a population-based study in Catalonia report that hospital care, 
medications and primary care appear to be the main drivers of costs in both type 2 diabetics and non-diabetics. 
6
 The original dataset comprises almost 830,000 observations, including the majority of the population living in 
the area. 
7
 The sample may include diabetics with zero utilisation in some of these years. These might be patients who 
had some positive use only in selected years. We dropped all individuals with type 1 diabetes.  
8




Our main variable of interest is uncontrolled type 2 DM, that we define using a dummy 
variable. Following the medical literature, we assume that diabetics are not adhering 
adequately to health treatments and hence not fully controlling their condition, when their 
within year mean HbA1c level is equal or above 7.5%. Since there is no universal consensus 
within the medical literature about the HbA1c thresholds which identify uncontrolled 
diabetes, we also estimate our models using a slightly lower threshold (7%).9 
It should be borne in mind that the dataset used in this study comes from a representative set 
of health care centres from Spain where health care is provided through a decentralised (at 
regional level) national health system, and provision is free of charge at the point of delivery 
with the exception of pharmaceuticals entailing some co-payments.10 
4. Empirical approach 
We focus on the effects of uncontrolled diabetes on three main outcomes: the number of GP 
and specialist visits and hospital length of stay. Given that these are non-negative integer 
outcomes and to exploit the panel element of our data, we estimate panel count data models 
that account for individual-level unobserved heterogeneity. More specifically, we present 
estimates on the effects of uncontrolled diabetes on the number of GP visits using negative 
binomial (NB) models with random effects (RE). This is a flexible specification that is often 
used to model health care utilisation in the economics literature as it goes beyond standard 
Poisson models allowing for overdispersion together with unobservables (e.g. Cameron and 
Trivedi, 2005; Sarma and Simpson, 2006).11  
 
We model the number of specialist visits and hospital length of stay using hurdle (two-part) 
models. Previous literature points out that the decision to contact a physician and the one 
concerning the amount of visits may be the result of two distinctive decision-making 
processes (e.g. Pohlmeier and Ulrich, 1995; Gerdtham, 1997; Deb and Trivedi, 2002). 
Further, these decisions might depend on both the individual and the physician, or more 
generally the heath care provider, and the complexity of this process may be exacerbated by 
repeated decisions in the presence of longitudinal data. This might also be the case in our data 
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 Results obtained using a lower threshold appear to be very similar and are available upon request. 
10
 During the period considered for this analysis (2004-2010), in Spain only individuals in employment would 
face a 40% copayment for prescribed medicines, whereas pensioners would be exempted. Furthermore, patients 
with chronic conditions would have a highly reduced copayment of 10% and civil servants would only pay 30% 
of the market price regardless of their employment status. 
11
 We have also estimated our models using Poisson specifications. Results are similar to the ones presented 
here and are available upon request. 
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when we analyse specialist visits (i.e. the decision to see a specialist vs. the number of visits) 
and hospital length of stay (i.e. the decision to walk into a hospital vs. length of stay) for 
patients with type 2 diabetes. Accordingly, we employ two-part or hurdle specifications to 
account for these two separate decisions. In our case, the first part of the hurdle is a probit 
model that distinguishes between users and non-users while the second part estimates the 
intensity of use (conditional on positive use) through a NB model with RE. This approach is 
also motivated by the relatively high frequency of zeros (non-use) for these two outcomes. 
All these models exploit variations in utilisation between the years 2004-2010 and account 
for a number of individual observable characteristics, individual-level unobserved 
heterogeneity, years and geographical area (local health authorities) fixed effects. Our basic 
specification is:  
 =		
	 +  +  +  +  + 											(i=1,…,N;t=1,…,T;j=1,…,J)             (1) 
where   is health care utilisation, that is alternatively the number of GP visits, specialist 
visits or hospital length of stay of individual i, in (health authority) area j at time t.	 	
 is 
our main variable of interest as it defines uncontrolled diabetes via the biomarker HbA1c. 
Following the medical literature, in our basic specification we define uncontrolled diabetes in 
the presence of within year average values of HbA1c ≥7.5%. This variable is lagged one 
period to ease concerns around endogeneity.12 We also estimate alternative specifications 
including a series of binary variables defining increasing levels of uncontrolled diabetes, i.e. 
7.5%≤HbA1c<8.5%; 8.5%≤HbA1c<9.5; and HbA1c≥9.5%. We do this to explore the 
potential presence of a gradient in health care utilisation driven by the severity of an 
individual’s condition.  is a vector that includes socio-demographic individual-level 
observable variables as well as clinically assessed health conditions. These include age (age, 
age squared and cubic age to capture non-linear age effects); labour market status (being 
active in the labour market contrasted against being inactive); immigration status (being a 
non-EU immigrant versus a Spanish or EU citizen as a baseline); marital status (living alone 
versus married/with a partner); health-behaviours (alcohol consumption, smoking status and 
objectively measured BMI) and a series of diabetes-unrelated chronic health conditions (e.g. 
asthma, chronic obstructive pulmonary disease (COPD), dementia, psychosis, clinical 
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 We have also estimated the full set of our models using contemporaneous values of HbA1c. Main results 
appear to be similar and estimates are available upon request.  
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depression and cancer).13 The time dummies  account for time trends while  identifies 
primary health authority areas (defined at geographical level) fixed effects.  represents 
individual-level time-invariant unobserved heterogeneity and  is the idiosyncratic error 
term.  
Conditionally correlated random effects  
To allow for correlation between observables and individual unobserved heterogeneity, we 
parameterise the individual effect  as a function of the within individual means of the 
exogenous regressors (see Mundlak, 1978; Chamberlain, 1984; Cameron and Trivedi, 
2013).14 This simply translates into including among our regressors the time-average of the 
time-varying exogenous (continuous) variables, i.e.	 . In our case, this includes the average 




We also provide a series of robustness checks to assess the validity of our main results. More 
specifically, we examine whether and to what extent the effects of poor glycemic control on 
utilisation are mediated by the number of patients’ health conditions. To purge our estimates 
from such influences, we run our models on a sample of “healthy users”, i.e., diabetics 
without the following diagnosed conditions: cardiovascular disease, cerebrovascular disease, 
neuropathy and heart failure. Furthermore, in order to separately account for individual-level 
unobserved heterogeneity and the effects of previous period (t-1) health care utilisation on 
current consumption, we also estimate dynamic NB models with RE. This approach extends 
the previous conditionally correlated random effects model already augmented by a Mundlak 
correction by including among our regressors values of the dependent variables lagged one 
period, 	
, as well as initial conditions in the parameterisation of the individual effect 
(Wooldrige, 2005).15 Note that these estimates are performed on a balanced panel sample 
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 Note that we exclude diabetes related health conditions (i.e. cardiovascular disease, cerebrovascular disease, 
neuropathy and heart failure) from our basic specifications. This is because we aim at identifying the effect of 
uncontrolled diabetes, together with other unrelated conditions, on utilisation. Further models reported among 
the robustness checks, include the full battery of health conditions.       
14
 For a more recent discussion on the use of the conditionally correlated (CCR) random effects models applied 
to count data models, including negative binomial models, see Cameron and Trivedi (2013). Note that since the 
random effect in negative binomial models applies to the distribution of the dispersion parameter, in this case, 
this Mundlak-type correction would only concern the variance of the model.  
15
 That is, we also include among our regressors initial (wave 1) values of our dependent variable, i.e. ,,.  
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where patients are observed during seven consecutive years (2004-2010) to allow accounting 
for initial conditions and values of the lagged dependent variables.  
5. Results 
Descriptive statistics 
The prevalence of DM in the full dataset of 104,000 patients (including diabetic and non-
diabetic patients) increased from 6.4% in 2004 to 9.3% in 2010. As expected, the prevalence 
is substantially higher for those aged 65+ (21.1% in 2004 versus 25.3% in 2010). These 
figures appear similar to those at national level in Spain for diagnosed diabetes during the 
same years (Soriguer et al., 2012; Vinagre and Conget, 2013). Our sub-sample of diagnosed 
type 2 diabetic patients defined using both physicians’ disease classification codes and blood 
tests reduces to 53,936 observations over the period 2004-2010.  
Table 1 reports descriptive statistics for both the sub-sample of all diabetics and the one that 
only includes patients with uncontrolled diabetes (HbA1c>=7.5%). Both samples of diabetic 
patients are broken down by gender. Within the full sample of diabetics, the mean numbers of 
GP visits per year are 11.27 (men) and 13.68 (women), while these reduce to 3.43 (men) and 
3.66 (women) in case of specialist visits and 0.56 (men) and 0.65 (women) for hospital length 
of stay. We also note that this sub-sample includes mainly older individuals with a mean age 
of 65.4 years. The mean HbA1c value in the sample is 7%, which is very close to the estimate 
mean figure for the whole region, Catalonia (7.15%). Importantly, and consistently with 
evidence reported in other developed countries, our dataset shows that a significant number 
of diabetic patients are not controlling adequately their condition despite the well-known 
potentially life-threatening health consequences caused by the diabetes-related complications: 
uncontrolled diabetes (HbA1c levels ≥ 7.5%) is as high as 30.53% (men) and 27.59% 
(women). For these patients health care consumption appears to be substantially higher, 
especially their primary care use: GP visits increase to 16.32 (men) and 20.18 (women), 
specialist visits to 4.68 (men) and 5.15 (women), while hospital length of stay grows only 
marginally to 0.63 (men) and 0.77 (women). Overall, diabetic women with and without 
uncontrolled diabetes appear to systematically consume more health care if compared to men 
and patients of both genders with uncontrolled diabetes present average HbA1c levels of 
around 8.7%. Men with poor glycemic control are slightly younger and more likely to be 
immigrants; living alone; consume alcohol and tobacco smoke; and have a higher BMI than 
diabetic men who better control their condition. Also, men with uncontrolled diabetes present 
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higher percentages of depression, heart diseases and dyslipidaemia (high values of lipids in 
blood such as cholesterol). Women who do not control adequately their blood sugar levels 
appear to be somewhat older; more likely to be outside the labour market; and also show 
increased percentages of alcohol and tobacco consumption and a higher BMI. This category 
of women also presents a higher incidence of depression, hypertension, dyslipidaemia, heart 
diseases and cardiovascular diseases. 
Our three main outcome variables appear to be highly right skewed distributed with a long 
tail indicating a very large consumption of resources by a small fraction of diabetic patients.16 
Another relevant feature of the dataset is the existence of 18% of zero GP visits during the 
years 2004-2010, and this increases to 38% (specialist visits) and 90% (hospital length of 
stay). As previously mentioned, the presence of overdispersion in the data concerning 
utilisation justifies the use of NB models. Yet, a zero mass problem in the data is judged to be 
of concern only in case of specialist visits and hospital length of stay, which explains our 
decision to examine such outcomes through a hurdle approach.17  
Main results 
In order to quantify the effects of uncontrolled diabetes (UD) on health care utilisation, we 
estimate a series of (static) NB2 models with random effects (RE) that exploit the 
longitudinal nature of the data and account for unobserved heterogeneity.18 All models 
employ conditionally correlated RE and are augmented by a Mundlak specification which 
includes the within mean of the continuous regressors. All models also include lagged values 
of the biomarker (HbA1c) defining UD to ease concerns around endogeneity and control for 
the full set of covariates. Since the medical literature appears to find higher percentages of 
poor control and non-adherence among males and this may have an impact on subsequent 
health care utilisation, we present separate estimates by gender on an unbalanced panel. All 
tables report average marginal effects.  
The first two columns of Table 2 show the estimates of our variable of interest, the lagged 
value of the biomarker detecting UD, on the number of GP visits for men and women. We 
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 For instance, the variance of GP visits is almost 13 times greater than its mean. The same applies to specialist 
visits (8 times) and hospital stays (21 times). 
17
 Once we condition on positive counts, the average number of specialist visits is 5.76 per year and the average 
length of stay is 5.9 days per year. 
18
 Specifically, we estimate the variant of the NB model in which the conditional variance function is quadratic 
in the mean, called negative binomial 2 (NB2). See Cameron and Trivedi (1998). 
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find that for men the effect of UD on the use of primary care is positive and highly 
statistically significant with a quantitative effect of around 0.48 GP visits. This represents an 
increase of almost 4% of the annual GP visits of men driven by poor glycemic control. 
Although the effect of UD on GP visits for women also appear to be positive, it is not 
statistically significant.  
In columns (3) and (4) we report the effects of UD on specialist visits using the hurdle RE 
NB2 model. Again, estimates appear to differ by gender as the quantitative effects are 
positive and statistically significant, pointing towards an increase in the number of specialist 
visits, only for diabetic men. We find that the effect of having HbA1c≥7.5% in the previous 
period leads an increase of specialist visits of 0.25 (at 5% significance level) conditional to 
positive visits. This corresponds to a percentage increase around 4.4 in the number of annual 
specialist visits. Finally, the last two columns of Table 2 present the effects of UD on hospital 
length of stay using the same hurdle approach. These models present a reduced number of 
observations as a consequence of a larger number of zeros in the data. Interestingly, we find 
again a gender pattern since UD is solely associated with a raise in the number of days in 
hospital among male patients. Specifically, the results indicate that one-year lagged 
uncontrolled DM leads to a statistically significant increase of 0.78 additional days in 
hospital, conditional to positive stays. This corresponds to an increase of around 17.4% in the 
annual length of stay. 
Since reduced glycemic control increases the risk of diabetes complications and this may in 
turn influence health care use, Table 3 examines potential non-linearities in the effects of UD 
by defining increasing levels of this condition: low (7.5%≤HbA1c<8.5%); moderate 
(8.5%≤HbA1c<9.5) and high (HbA1c>=9.5%) UD. Our estimates show that the raise in GP 
visits among diabetic men appear to be mainly concentrated among those with low and 
moderate levels of UD with increases of around 0.4 and 0.7 GP visits respectively. Among 
men, we also find statistically significant effects of low and high UD on specialist visits with 
the largest impact observed for diabetic with the poorest control (high UD). Our estimates 
show that having low and high UD in the previous year lead to annual increases of 0.26 and 
0.46 specialist visits respectively, conditional to positive visits. These correspond to average 
increases of roughly 4.5% and 8%. Men also present a positive, large and highly statistically 
significant effect of low UD and only a weekly significant effect (although also large) of high 
UD on hospital length of stay. The effect of low UD on utilisation implies an additional 1.1 
day in hospital, representing a mean annual increase in the length of stay, conditional on 
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hospital admission, of around 25%. It should be noted that for women, none of the effects 
related to UD appear to be statistically significant.  
Table 4 presents estimates from RE NB2 as well as hurdle RE NB2 for a sub-sample of 
healthy-users. In this case, we have excluded from our analysis individuals with diabetes 
complications as these may increase the level of health care consumption and potentially 
confound our effects of interest. These estimates should help us identifying the effects of UD 
on health care consumption purged from related health care complications. Estimates appear 
to substantially confirm the ones presented in Table 2. Among men, we find statistically 
significant effects of UD on both GP and specialist visits. These effects appear to be 
quantitatively larger if compared to the results obtained from the more general sample of 
diabetics in Table 2. This may imply that for men, increases in health care consumption 
might be mainly driven by UD and not necessarily its related complications. We also find a 
weakly significant effect of UD on hospital length of stay, conditional on admission. As for 
the previous models in Tables 2 and 3, we do not detect any effects for women that are 
statistically different from zero. 
Table 5 includes results from dynamic RE NB2 and hurdle models on a balanced sample. 
These models were implemented with the specific purpose of separately accounting for both 
individual unobserved heterogeneity and the dynamics of health care consumption together 
with the influence of UD. Statistically significant persistence of health care consumption 
appears to be present for both genders and for both GP and specialist visits. However, this 
does not appear to play a major role among the determinants of hospital length of stay for 
men and also present a negative effect on consumption for women. This is expected and 
might be related to the different nature and frequency of health consumption identified by the 
three outcomes considered: hospital admission is a much rarer event if compared to GP and 
specialist visits. Interestingly, in this case we find statistically significant effects of UD on GP 
visits among women and only on specialist visits amongst men, although only significant at 
10%.19 In any case, we should be cautious in the interpretation of the effects of past heath 
care consumption on current use because these might be also partly driven by previous 
(further back in time) levels of UD. In any case, given the substantial drop in the number of 
observations when using a balanced sample, we should be cautious in comparing these 
estimates with our main results.  
                                                          
19
 We also run the same dynamic specifications on an unbalanced sample and we found similar effects to those 
reported in Table 2. These findings are also available upon request. 
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6. Conclusions and discussion  
Very little is known on the effects of non-adherence to health treatments on health care 
utilisation, especially among individuals with chronic conditions and diabetes. Previous 
evidence is mixed, often based on limited data and standard linear models as well as self-
reported information that may be plagued by reporting bias. Other literature focused on the 
effects on labour supply and aspects of quality of life while the consequences on health care 
utilisation of non-adherence and uncontrolled diabetes have not been examined. In this paper, 
we employ detailed longitudinal data on a large population of adult diabetic patients and use 
a clinically assessed biomarker to detect the presence of uncontrolled diabetes and in turn its 
influence on GP visits, specialist visits and hospital length of stay. We focus on these 
outcomes as they appear to account for the largest components of medical costs associated to 
diabetes complications.  
We estimate a range of panel count data models, including negative binomials with random 
effects, dynamic and hurdle specifications to account for unobserved heterogeneity, previous 
utilisation and selection. The inadequate control of diabetes, the most widespread chronic 
condition in all developed countries, and the analysis of its multiple determinants is a key 
priority for health care professionals and policy makers. 
Our analysis confirms that a large fraction of diabetic patients (30%) appears to have a poor 
control of their condition and this leads to an excess healthcare utilisation, especially among 
men. We find that among men, uncontrolled diabetes appears to increase the number of GP 
visits by around 4% and the volume of  specialist visits, also by about 4.4%, after accounting 
for a wide set of controls and other clinically assessed conditions. Our findings also indicate 
that uncontrolled diabetes leads to an increase of around 17.4% in the annual hospital length 
of stay for men, conditional on positive stays. This may imply that, although hospitalisation is 
a relatively rare event for diabetic patients, uncontrolled diabetes greatly increases its length, 
therefore imposing additional costs to the health system. Although women with diagnosed 
diabetes appear to consistently consume more health care if compared to men, their 
consumption do not appear to be driven by uncontrolled diabetes.  
Interestingly, our analysis appears to show heterogeneous effects among men. For instance, 
we find that the increase in GP visits among diabetic men is concentrated among those with 
low (7.5%≤HbA1c<8.5%) and moderate (8.5%≤HbA1c<9.5) levels of uncontrolled diabetes. 
Yet, the annual increase in specialist visits, conditional to a positive number of visits, concern 
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patients having low and high (HbA1c>=9.5%) levels of inadequate control. Finally, we find 
that increase in the length of stay (around 25%) appears to be concentrated among patients 
with low levels of uncontrolled diabetes. We believe these latter findings might be 
particularly informative as they identify specific groups of diabetics that should be targeted 
and prioritised in order to use health resources more efficiently and provide better treatments. 
Our robustness checks appear to validate our main findings. 
Overall, this study combines the use of robust panel econometric methods with rich 
administrative data to estimate for the first time the effects of non-adherence on health care 
utilisation by focusing on diabetes, one of the most widespread chronic conditions 
worldwide. Our results suggest that improving glycemic control would not just be beneficial 
to patients’ wellbeing but would also substantially reduce extra health care utilisation. 
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Table 1: Descriptive statistics: Years 2004-2010 
 Entire sample of Diabetics  Diabetics with HbA1c ≥ 7.5% 
 Men  N Women  N  Men N Women N 
GP Visits 11.27  26964 13.68  26972  16.32 4432 20.18 4096 
Specialist visits 3.43  26964 3.66  26972  4.68 4432 5.15 4096 
Hospital stays 0.56  26964 0.65  26972  0.63 4432 0.77 4096 
HbA1c level 7.08  14515 7.00  14848  8.69 4432 8.68 4096 
Uncontrolled DM * 30.53  14515 27.59  14848  - 4432 - 4096 
            
Age 64.47  26964 66.42  26972  63.54 4432 67.66 4096 
Immigrant 2.31  26964 3.12  26972  2.73 4432 2.37 4096 
Active 32.87  26860 25.39  26789  34.46 4422 18.45 4075 
Living alone 88.57  26964 83.15  26972  90.55 4432 83.76 4096 
Alcohol 5.11  26964 0.56  26972  5.80 4432 0.71 4096 
Tobacco 28.39  26964 8.14  26972  33.73 4432 8.64 4096 
BMI 29.13  25165 30.81  24576  29.31 4352 31.73 4017 
Asthma 1.86  26964 6.05  26972  1.65 4432 6.81 4096 
CPOD 9.81  26964 2.68  26972  9.05 4432 2.54 4096 
Dementia 2.00  26964 3.56  26972  1.65 4432 2.91 4096 
Psychosis 1.11  26964 1.10  26972  1.08 4432 0.66 4096 
Depression 9.55  26964 23.12  26972  10.24 4432 28.32 4096 
Neoplasia 8.52  26964 7.00  26972  5.75 4432 6.91 4096 
Hypertension 50.72  26964 60.91  26972  49.99 4432 68.04 4096 
Dyslipidemia 47.47  26964 47.45  26972  50.10 4432 57.84 4096 
Heart Diseases 16.27  26964 8.57  26972  17.89 4432 9.38 4096 
Cerebrovasc D. 5.76  26964 1.81  26972  6.34 4432 3.03 4096 
Heart failure 12.91  26964 12.54  26972  11.17 4432 12.06 4096 
Neuro 0.92  26964 1.27  26972  0.81 4432 1.20 4096 
*




Table 2: The effects of uncontrolled diabetes on health care utilisation  
   Hurdle Models   
 (1) (2) (3) (4) (5) (6)   
 Men Women Men Women Men Women   
 GP visits GP visits  Specialist  Specialist  Hosp. Stays  Hosp. Stays    
UD (t-1) 0.483** 0.241 0.249** 0.155 0.777** 0.111   
 (0.192) (0.230) (0.119) (0.127) (0.316) (0.369)   
         
N 11763 12147 9235 9924 1394 1574   
UD (t-1) stands for uncontrolled type 2 diabetes as measured by HbA1c>=7.5% lagged one period. Table 
displays average marginal effects (AME) for static RE NB2 model augmented by a Mundlak specification 
(unbalanced sample). All models control for the full set of covariates. Standard errors in parentheses. * p < 0.10, 
**
 p < 0.05, *** p < 0.01.  
 
 
Table 3: The effects of uncontrolled diabetes on health care utilisation - HbA1c levels 
   Hurdle Models   
 (1) (2) (3) (4) (5) (6)   
 Men  Women   Men  Women  Men  Women    
 GP 
visits 





UD1 [7.5, <8.5%] (t-1) 0.412** 0.310 0.261** 0.122 1.099*** 0.058   
 (0.210) (0.248) (0.130) (0.137) (0.353) (0.401)   
         
UD2 [8.5, <9.5%] (t-1) 0.669** 0.343 0.125 0.245 -0.014 0.393   
 (0.303) (0.360) (0.187) (0.195) (0.468) (0.524)   
         
UD3 [>=9.5%] (t-1) 0.582 -0.504 0.459** 0.206 1.027* -0.335   
 (0.384) (0.449) (0.232) (0.244) (0.553) (0.680)   
         
N 11763 12147 9235 9924 1394 1574   
UD1,2,3 (t-1) stands for the uncontrolled type 2 diabetes defined within the corresponding HbA1c interval 
lagged one period. All models present average marginal effects (AME) for static RE NB2 models augmented by 
a Mundlak specification (unbalanced panel). All models control for the full set of covariates. Standard errors in 





Table 4: The effects of uncontrolled diabetes on health care utilisation – healthy users 
   Hurdle Models   
 (1) (2) (3) (4) (5) (6)   
 Men Women Men Women Men Women   
 GP visits GP visits  Specialist  Specialist  Hosp. Stays  Hosp. Stays    
UD (t-1) 0.560** 0.097 0.286** 0.216 0.718* 0.066   
 (0.219) (0.248) (0.139) (0.141) (0.368) (0.423)   
         
N 8179 9466 6180 7633 832 1125   
UD (t-1) stands for uncontrolled type 2 diabetes as measured by HbA1c>=7.5% lagged one period. Table 
displays average marginal effects (AME) for static RE NB2 model augmented by a Mundlak specification 
(unbalanced sample). All models control for the full set of covariates. Standard errors in parentheses. * p < 0.10, 
**
 p < 0.05, *** p < 0.01.  
 
Table 5: The effects of uncontrolled diabetes on health care utilisation – dynamic 
models  
   Hurdle Models 
  
 (1) (2) (3) (4) (5) (6) 
  
 Men Women Men Women Men Women 
  
 GP visits GP visits  Specialist  Specialist  Hosp. Stays  Hosp. Stays  
  
UD (t-1) 0.431 0.871*** 0.380* 0.001 -0.131 -0.523 
  
 (0.292) (0.310) (0.198) (0.183) (0.478) (0.495) 
  
       
  
GP visits (t-1) 0.186*** 0.106*** - - - - 
  
 (0.0137) (0.0106)     
  
 
Spec. visits (t-1)            
 














Hosp. stays (t-1) - - - - 0.056 -0.069** 
  
N 3738 4704 3122 4094 468 602 
  
UD (t-1) stands for uncontrolled type 2 diabetes as measured by HbA1c>=7.5% lagged one period; GP visits (t-
1) stands for the number of GP visits lagged one period; Spec. visits (t-1) for number of specialist visits lagged 
one period; Hosp. Stays (t-1) for the length of hospital stays lagged one period. Table displays average marginal 
effects (AME) for dynamic RE NB2 model augmented by initial conditions and a Mundlak specification 
(balanced sample). All models control for the full set of covariates. Standard errors in parentheses. * p < 0.10, ** 
p < 0.05, *** p < 0.01.  
 
